Biotechnology
HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stag...
2025-10-20 19:00
1226
Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- The research team led by Dr. Yuejun Chen , founder of UniXell Biotech, published online an article titled "3D-Cultured Human Medium Spiny Neurons Achieve Functional Integration into Huntingtin Disease Mouse Neural Circuits and Improve Motor Deficits" in the ...
2025-10-20 18:13
834
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). * OS was significantly longer with sac-TMT than with chemotherapy (H...
2025-10-20 17:06
1183
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened inBerlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma no...
2025-10-20 14:20
998
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances Accord B.V.'s commitment to improving global a...
2025-10-20 14:00
1150
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor rece...
2025-10-20 13:59
975
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colore...
2025-10-20 13:15
1140
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-s...
2025-10-20 10:36
1122
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...
2025-10-20 09:00
1058
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041)...
2025-10-20 08:15
1198
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) ofsmall molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight. - The ult...
2025-10-20 08:10
1301
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2025-10-20 07:00
1116
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
* Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. * The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination th...
2025-10-19 23:37
1340
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients with melanoma and gyneco...
2025-10-19 15:00
2529
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically...
2025-10-19 14:00
1541
SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigato...
2025-10-18 13:00
2459
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients with heavily pretreated EGFR Wild-type NSCLC and ...
2025-10-17 22:00
3506
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for marketi...
2025-10-17 20:22
1851
Chula Launches Newborn Genome Sequencing Project for Early Detection and Prevention of Genetic Diseases
BANGKOK, Oct. 17, 2025 /PRNewswire/ -- The Center of Excellence in Medical
Genetics
2025-10-17 16:00
1309
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
* New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide * Intention to pursue a Hong Kong initial public offering (IPO) to expand ...
2025-10-17 15:21
2345
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 311 media titles]
2025-12-04 16:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 301 media titles]
2025-12-09 13:31
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4404
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3598
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3564
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
3259